ERNA - Eterna Therapeutics Inc.

0.1716
-0.015   -8.625%

Share volume: 277,864
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$0.19
-0.01
-0.08%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
27%
Profitability 0%
Dept financing 28%
Liquidity 41%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-9.25%
1 Month
-36.63%
3 Months
-41.83%
6 Months
-41.83%
1 Year
-41.83%
2 Year
-41.83%
Key data
Stock price
$0.17
P/E Ratio 
0.00
DAY RANGE
$0.17 - $0.19
EPS 
$3.91
52 WEEK RANGE
$0.15 - $0.33
52 WEEK CHANGE
-$41.83
MARKET CAP 
15.104 M
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$243,224
AVERAGE 30 VOLUME 
$217,999
Company detail
CEO: Matthew Angel
Region: US
Website: brooklynitx.com
Employees: 10
IPO year: 2006
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Brooklyn ImmunoTherapeutics, Inc. engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology.

Recent news
loading